Volume 1, Issue 1, Pages 19-27 (January 2019) Prophylactic Right Ventricular Assist Device for High-Risk Patients Undergoing Valve Corrective Surgery Atul Jaidka, MD, Sabe De, MD, FRCPC, FASE, A. Dave Nagpal, MD, FRCSC, Michael W.A. Chu, MD, FRCSC CJC Open Volume 1, Issue 1, Pages 19-27 (January 2019) DOI: 10.1016/j.cjco.2018.10.001 Copyright © 2018 Canadian Cardiovascular Society Terms and Conditions
Figure 1 Perioperative photographs showing (A) pulmonary artery cannulation (white arrow), right atrium cannulation (blue arrow), (B) cannula externalization, (C) Thoratec CentriMag (Thoratec Corporation, Pleasanton, CA), and (D) patient mobilization with right ventricular assist device (RVAD) (red arrow). CJC Open 2019 1, 19-27DOI: (10.1016/j.cjco.2018.10.001) Copyright © 2018 Canadian Cardiovascular Society Terms and Conditions
Figure 2 Number of days after primary operation for each patient and dose of (A) milrinone and (B) epinephrine. Larger and unfilled circular markers represent day of RVAD explantation. OR, operation. CJC Open 2019 1, 19-27DOI: (10.1016/j.cjco.2018.10.001) Copyright © 2018 Canadian Cardiovascular Society Terms and Conditions
Figure 3 (A) Right ventricular (RV) systolic function, (B) tricuspid annular plane systolic excursion, (C) RV size, and (D) RV end-diastolic diameter graded by echocardiography preoperatively, postoperatively, and at last follow-up. RV, right ventricle; TAPSE, tricuspid annular plane systolic excursion. CJC Open 2019 1, 19-27DOI: (10.1016/j.cjco.2018.10.001) Copyright © 2018 Canadian Cardiovascular Society Terms and Conditions
Figure 4 Early and late survivals of patients. OR, operation. CJC Open 2019 1, 19-27DOI: (10.1016/j.cjco.2018.10.001) Copyright © 2018 Canadian Cardiovascular Society Terms and Conditions